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Summary
Nail-patella syndrome (NPS), a pleiotropic disorder ex-
hibiting autosomal dominant inheritance, has been stud-
ied for 1100 years. Recent evidence shows that NPS is
the result of mutations in the LIM-homeodomain gene
LMX1B. To determine whether specific LMX1B muta-
tions are associated with different aspects of the NPS
phenotype, we screened a cohort of 41 NPS families for
LMX1B mutations. A total of 25 mutations were iden-
tified in 37 families. The nature of the mutations sup-
ports the hypothesis that NPS is the result of haploin-
sufficiency for LMX1B. There was no evidence of
correlation between aspects of the NPS phenotype and
specific mutations.
Introduction
Nail-patella syndrome (NPS [MIM 161200]), or ony-
cho-osteodysplasia, is an autosomal dominant, pleiotro-
pic disorder characterized by dysplastic nails, absent or
hypoplastic patellae, exostoses (“horns”) of the ilia, dys-
plasia of the elbows, and, in some cases, nephropathy
(Beals and Eckhardt 1969). Recent evidence suggests
that glaucoma may also be part of the syndrome (Lichter
et al. 1997). NPS was first recognized as an inherited
disorder by Little (1897), who reported a four-genera-
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tion pedigree with 18 affected members who had absent
patellae and thumbnails. The independently mapped in-
cidence is estimated at 1 in 50,000 live births.
Genetic linkage between NPS and the ABO blood
group was first reported 140 years ago (Renwick and
Lawler 1955) and was subsequently localized to the in-
terval between D9S315 and D9S2172 (McIntosh et al.
1997; Eyaid et al., in press). Recently, Dreyer et al.
(1998) demonstrated that NPS is the result of mutations
within the LMX1B gene. At the same time, Chen et al.
(1998) showed that mice ablated for Lmx1b exhibited
skeletal pathology similar to NPS. Iannotti et al. (1997)
independently mapped LMX1B to 9q34, and Vollrath
et al. (1998) mapped LMX1B within the NPS candidate
interval and identified four mutations that segregate with
the NPS phenotype in unrelated families. The available
evidence suggests that NPS results from heterozygosity
for loss-of-function mutations in LMX1B (Dreyer et al.
1998; Vollrath et al. 1998).
LMX1B is a member of a diverse family of regulatory
proteins characterized by the presence of two zinc-finger
structures and a homeodomain (Curtiss and Heilig
1998). The homologous gene in the chick has been im-
plicated in the dorsoventral patterning of the developing
limb bud (Riddle et al. 1995; Vogel et al. 1995). Com-
parison of the phenotype observed in Lmx1b-ablated
mice with NPS suggests that the skeletal phenotype is
the result of a deficiency in dorsoventral patterning dur-
ing development. Specifically, Lmx1b / mice dem-
onstrated ventralization of dorsal-limb characteristics
(e.g., absence of claws and patellae and duplication of
ventral structures such as foot pads and ventral-specific
tendons and musculature). In addition, renal pathology
similar to that seen in NPS was observed (Chen et al.
1998). To determine whether specific mutations within
LMX1B were responsible for certain aspects of NPS, we
undertook mutation analysis of a cohort of 41 families.
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Table 1
Summary of Phenotypic Information Provided by Study Participants
Family
No. of
Affected Members
Nail
Hypoplasia
Patella
Hypoplasia
Elbow
Hypoplasia Iliac Horns Nephropathy Clubfoot
2 14 13/14 9/14 5/14 Unknown Unknown Unknown
4 10 10/10 7/9 9/10 1/2 2/3 2/9
5 9 9/9 9/9 7/8 4/5 1/1 2/9
7 6 6/6 4/4 5/6 1/1 0/1 1/6
8 2 2/2 2/2 2/2 Unknown Unknown 0/2
9 1 (S) 1/1 1/1 1/1 1/1 1/1 1/1
10 2 1/2 2/2 2/2 1/2 1/2 1/2
12 2 2/2 2/2 2/2 2/2 2/2 0/2
14 8 8/8 8/8 6/7 5/5 3/7 1/7
17 2 2/2 1/2 0/2 1/1 0/1 0/2
20 1 (S) 1/1 1/1 1/1 1/1 1/1 0/1
21 5 5/5 4/5 5/5 4/4 1/2 1/5
23 2 0/1 2/2 2/2 2/2 0/2 1/2
25 2 2/2 2/2 2/2 1/1 1/2 0/2
26 2 1/2 2/2 2/2 Unknown Unknown 0/1
30 1 (S) 1/1 1/1 1/1 Unknown Unknown 1/1
31 1 (S) 1/1 1/1 1/1 1/1 1/1 1/1
32 1 (S) 1/1 Unknown 1/1 Unknown Unknown 0/1
34 1 (S) 1/1 1/1 1/1 1/1 1/1 1/1
35 3 3/3 2/3 2/3 2/2 0/2 0/3
42 1 1/1 1/1 1/1 Unknown 1/1 0/1
44 3 3/3 2/2 2/2 1/1 Unknown 0/2
47 1 1/1 1/1 1/1 1/1 1/1 0/1
52 3 3/3 3/3 0/1 3/3 Unknown 1/3
53 1 1/1 1/1 1/1 Unknown Unknown 0/1
54 3 3/3 2/2 1/2 1/1 Unknown 0/3
55 2 2/2 2/2 2/2 2/2 1/1 1/2
56 5 5/5 5/5 5/5 0/3 1/4 0/5
57 2 2/2 2/2 1/2 Unknown Unknown 0/2
60 2 2/2 2/2 2/2 Unknown 1/2 0/2
65 2 2/2 2/2 2/2 2/2 1/2 1/2
66 1 (S) 1/1 1/1 1/1 1/1 1/1 1/1
67 1 (S) 1/1 1/1 1/1 Unknown 0/1 0/1
68 1 (S) 1/1 1/1 1/1 Unknown 0/1 1/1
69 1 (S) 1/1 1/1 Unknown Unknown 1/1 0/1
70 1 (S) 1/1 1/1 1/1 Unknown 0/1 0/1
71 1 (S) Unknown 1/1 1/1 Unknown 1/1 Unknown
Total 91 100/104 90/100 80/99 39/46 24/46 18/87
NOTE.—Ssporadic; Unknownunknown, not tested, or no comment.
Subjects and Methods
Patient Samples
Families 1–5 have been described elsewhere (McIntosh
et al. 1997). Additional families and patients with spo-
radic cases of NPS were identified from clinic records
or were referred to us. In each case, at least the proband
was diagnosed by a clinical geneticist, orthopedist, or
pediatrician. Appropriate informed consent was ob-
tained from each individual. The clinical findings within
each family are summarized in table 1. In most cases,
information was provided directly by the affected in-
dividuals or by their parent(s). Only qualitative results
are shown; no quantification of severity has been at-
tempted. Not all family members had been tested for
each manifestation of the syndrome at the time they were
sampled, and some manifestations (e.g., glaucoma) may
not yet be present because of age-related penetrance. In
multiplex families, haplotyping with markers around the
NPS locus (McIntosh et al. 1997) did not reveal any
inconsistencies with linkage of the phenotype to chro-
mosome 9q34 (data not shown).
DNA Analysis
Genomic DNA was extracted from whole blood as
described by Bellus et al. (1995a). Mutations were iden-
tified via a combination of mutation-detection enhance-
ment (MDE) gel analysis and DNA sequencing (Bellus
et al. 1995b; Dreyer et al. 1998). We used the PCR
primers used by Dreyer et al. (1998), except for exons
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1 and 2, which we amplified with primers LMX-1F 5′-
GGCAGACGGACTGCGCC, LMX-1R 5′-TGTCCA-
CAGCCGGACGAC, LMX-2F 5′-CCCGGTGCGA-
CCGGGAC, and LMX-2R 5 ′-TGACCGGGCTC-
GAGTGC.
Segregation of mutations with the NPS phenotype was
confirmed by restriction-enzyme digest or allele-specific
oligonucleotide hybridization (Bellus et al. 1995b). Sim-
ilarly, a population of 100 people unaffected with NPS
was analyzed to show that missense mutations identified
in patients were not benign variants.
Homeodomain Expression and DNA Binding
Wild-type and mutant homeodomains containing mis-
sense mutations in the N-terminal region, helix 1, and
helix 2 were generated by in vitro transcription/trans-
lation of the pcDNA-5′ UT FLAG vector (Lefebvre et al.
1997) containing the respective mutant and wild-type
cDNAs. The expression constructs were generated by
cloning of mutagenized PCR products into the pcDNA-
5′UT FLAG vector at the BamHI and EcoRI restriction
sites, followed by confirmation with DNA sequencing.
Mutations were introduced into the homeodomains by
the two-step PCR mutagenesis method described by Au-
subel et al. (1994). Wild-type homeodomains (amino
acids 186–285) were PCR amplified with primers HD5′
and HD3′. For mutant homeodomains, two rounds of
amplifications were performed: first, HD5′ with MUT3′
and MUT5′ with HD3′, and then, finally, with HD5′ and
HD3′. For the respective mutations, the sequences of
primers were as follows (nucleotide mutations are un-
derlined): HD5′, 5′-GCAAGGGATCCGGGGATGAC-
GGG-3′; HD3′, 5′-GCCAGCGAATTCTAGGAAGC-
CATCAT-3′; MUT5′(A213P), 5′-CAGCAGCGAAGA-
GCCTTCAAGCCCTCCTTCGAGGTC-3 ′; MUT3 ′
(A213P), 5′-GACCTCGAAGGAGGGCTTGAAGGCT-
CTTCGCTGCTG-3′; MUT5′(R200Q), 5′-CGGAGG-
CCCAAGCGACCCCAGACCATCCTCACCAC-3 ′;
M U T 3 ′ ( R 2 0 0 Q ) , 5 ′ - G T G G T G A G G AT G G T-
CTGGGGTCGCTTGGGCCTCCG-3′; MUT5′(R226P),
5 ′-GCCTTGCCGAAAGGTCCCAGAGACACTGG-
CAGCTG-3′; and MUT3′(R226P), 5′-CAGCTGCCA-
GTGTCTCTGGGACCTTTCGGCAAGGC-3′.
Parallel in vitro transcription/translation reactions
were performed separately with unlabeled and labeled
[35S]methionine. The efficiency of the reaction and quan-
tity of protein were estimated by SDS PAGE. The ex-
pected product was 100 amino acids in length, and 3 ml
of the in vitro transcribed/translated product and 10
fmol of the [32P]end-labeled FAR/FLAT sequence probe
were used in electrophoretic mobility shift assay (EMSA)
experiments as described elsewhere (Johnson et al.
1997).
Results
Since mutations within the homeodomain are often
the cause of genetic disease (Engelkamp and van Hey-
ningen 1996), we first sequenced this region of LMX1B
in an affected person from each of the 41 families in the
cohort. The remainder of the gene was screened for mu-
tations by performing MDE gel heteroduplex analysis.
A total of 25 mutations were identified in 37 of the 41
families (tables 1 and 2).
Four novel frameshift mutations were identified that
would result in the incorporporation of a novel poly-
peptide sequence prior to the occurrence of a premature
termination codon (table 2, fig. 1). The single-base de-
letions, 320delG and 534delG, were identified in spo-
radic cases and were not present in either parent. The
precise extent of the larger deletion/insertion mutations,
485ins8 and 611del7, was determined by cloning and
sequencing of each allele. Each of the larger mutations
was identified in a small family and was present only in
persons with NPS.
All the other mutations identified were single-base
substitutions comprising eight nonsense mutations, five
putative splice mutations, and six missense mutations.
A single nonsense mutation, Y146X, was identified prior
to the homeodomain; the others were within the hom-
eodomain. Two of the nonsense mutations, R198X and
R208X, were recurrent mutations that have been de-
scribed elsewhere, in unrelated families (Dreyer et al.
1998; Vollrath et al. 1998). The R198X mutation was
observed in two small families, and R223X was found
in two unrelated families and a sporadic case.
We identified five putative splice mutations—
711GrA, 2572TrC, 6881GrA, 6881GrT, and
7651GrA—that would be predicted to result in exon
skipping. Among adult tissues tested, only kidney tissue
expressed LMX1B (Dreyer et al. 1998). No RNA was
available from any person carrying a splice mutation to
analyze for confirmation of the predicted effects or for
assessment of mRNA stability.
Among the six missense mutations identified, one,
C142W, affects a highly conserved cysteine residue
within the LIM-B domain. It segregated with the NPS
phenotype in one family and was not detected in a sam-
ple of 100 unrelated non-NPS control individuals (data
not shown). The other five missense mutations were
within the homeodomain (fig. 1) and in three instances
proved to have variable effects on DNA binding (see
below). The N246K mutation in helix 3 of the hom-
eodomain was found to recur in an individual unrelated
to the one in whom it had been reported previously
(Dreyer et al. 1998). Another mutation, R200Q, was
observed in five unrelated families and represents the
most common NPS mutation identified to date. Analysis
of parents showed that this was a de novo occurrence
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Table 2
Mutations Identified in NPS Patients Arranged by Domain and Then Mutation Type
Mutation Nucleotidea Domain Detection Putative Effect Familiesb
711GrA 711GrA LIM-A AluI Loss of exon 2, frameshift, PTC 21
2572TrC 2572TrC LIM-A Cac8I Loss of exon 2, frameshift, PTC 4
320delG 320delG LIM-B Sequence Frameshift, PTC 71
C142W C426G LIM-B ASO 2 Structure? 57
Y146X C438A LIM-B DdeI PTC 56
485ins8 485insACTCCGGT Linker RsaI Frameshift, PTC 8
534delG 534delG Linker Sequence Frameshift, PTC 31
R198X C592T HD MaeIII PTC 12, 25, 67 (D)
R200Q G599A HD MspI DNA binding 10, 26, 32, 34, 47
611del7 611del7 HD ASO Frameshift, PTC 44
R208X C622T HD ASO PTC 554
A213P G637C HD HaeIII DNA binding 20, 55, 66
E216X G646T HD TaqI PTC 14
S218P T652C HD NlaIV DNA binding? 30
R223X C667T HD ASO PTC 7, 9, 52
6721GrA 6721GrA HD ASO Loss of exon 4, frameshift, PTC 35
6721GrT 6721GrT HD ASO Loss of exon 4, frameshift, PTC 60
R226X C676T HD Sequence PTC 23
R226P G677C HD Sequence DNA binding 70
A230V C689T HD PvuII DNA binding? 2
697insA 697insA HD Sequence Frameshift, PTC 69 (D)
W243X G728A HD MaeI PTC 17
Q245X C733T HD Sequence PTC 53
N246K C738A HD Sequence DNA binding 42, 68 (D)
7501GrA 7501GrA HD ASO Loss of exon 5 65
NOTE.—HDhomeodomain; ASOallele-specific oligonucleotide hybridization; and PTCpremature termination
codon.
a Nucleotide numbering follows GenBank AF057135.
b Numbers refer to the families in which the mutations were identified (see Table 1). (D) indicates first described by
Dreyer et al. (1998) in the families indicated.
in three of five unrelated families. Similarly, the A213P
mutation in helix 1 of the homeodomain was observed
in three unrelated families. The recurrence of the A213P
and N246K mutations cannot be explained by presence
of a CpG hotspot.
Missense mutations in the homeotic domain affected
DNA binding to the FAR/FLAT sequence element of the
rat insulin promoter to various extents. The R200Q and
R226P mutations affect highly conserved arginine resi-
dues in the N-terminal arm and helix 2 of the homeo-
domain, respectively. They both reduced DNA binding
but did not abolish it in the in vitro assay. In contrast,
the A213P mutation abolished DNA binding to the FAR/
FLAT element (fig. 2). The in vitro studies suggest that
the clinical phenotype arises because of loss of function
of the mutated gene product and that different mutations
affect DNA binding in different ways. However, the ex-
tent of this effect in vivo is unclear.
Discussion
In our screening of 41 NPS families, we have identified
25 mutations in 37 families (fig. 1, table 2). The locations
of the remainder remain unknown at this time. In each
of these multigenerational families, the results of geno-
typing with polymorphic markers around the NPS locus
were consistent with linkage to 9q34 (data not shown).
It is possible that some mutations in exons 3, 7, and 8
were not detected by MDE gel analysis, although this
methodology has proved successful previously and de-
tected mutations in exon 3 and neutral polymorphisms
upstream of exon 7 (data not shown). Mutations may
reside within the promoter sequences; this possibility is
attractive, since it appears that NPS is the result of hap-
loinsufficiency (see below), and reduced transcription of
one allele could effectively mimic the effect of a nonsense
mutation. It is also possible that a substantial portion
of LMX1B has been deleted in these families. To assess
this possibility, we performed Southern blot analysis
with multiple restriction-enzyme digests of genomic
DNA; no differences were observed between patients
and controls (data not shown). Furthermore, analysis of
a TaqI polymorphism within the coding region (identi-
fied during mutation screening and also described by
Vollrath et al. [1998]) showed that each family included
at least one affected member heterozygous for exon
4—that is, this exon was present within the mutant
allele.
We found six point mutations to have recurred in
unrelated individuals. In at least one instance for each
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Figure 2 Homeodomain DNA binding. A, SDS-PAGE of in vitro
transcribed/translated wild-type and mutant homeodomains. The ar-
row indicates the translated protein. Mr  relative molecular weight.
B, EMSA of wild-type and mutant homeodomains to FAR/FLAT se-
quence probe. The thicker arrow indicates DNA-homeodomain com-
plex; the thinner arrow indicates the free DNA probe.
Figure 1 Relative positions of NPS mutations within LMX1B gene product. Nonsense mutations are above the gene product, missense
mutations below. The portions of the gene product altered by frameshift mutations are indicated at the top. The positions of intron-exon
boundaries are indicated by dotted lines, the boundaries between domains by solid lines. For comparison, mutations described elsewhere are
included (Dreyer et al. 1998; Vollrath et al. 1998). HD denotes homeodomain.
mutation, de novo occurrence was documented. In cases
where the mutations were segregating within families,
haplotype analyses showed that the mutations had re-
curred on distinct chromosomal backgrounds (data not
shown). The recurrence of mutations R198X, R200Q,
R208X, and R223X is not unexpected, since each is the
result of a transition at a CpG dinucleotide. CpG din-
ucleotides are believed to be hypermutable because of
deamination when they are methylated (Cooper et al.
1997). Conversely, A213P and N246K result from trans-
versions, and their recurrence cannot be explained by
this mechanism.
It has been suggested that NPS results from loss-of-
function mutations in LMX1B, that is, haploinsuffi-
ciency (Dreyer et al. 1998; Vollrath et al. 1998). Com-
parison of the mutations identified here (table 2) with
those described elsewhere does not provide evidence to
contradict the hypothesis. Since premature termination
codons most often result in instability of the mutant
mRNA as well as a shortened protein product (Maquat
et al. 1995), it is unlikely that the products of frameshift
and nonsense mutations can dramatically affect the func-
tion of the normal gene product through a dominant-
negative mechanism. It is not possible to eliminate the
possibility, however, since RNA from LMX1B-express-
ing tissues is not readily available. Furthermore, a bal-
anced chromosomal translocation involving 9q34.1 has
been observed to result in NPS in the absence of other
anomalies (Duba et al. 1998); a child of the individual
analyzed by Duba et al. (1998) exhibited partial trisomy
for 9q34.1 associated with various anomalies, but not
features of NPS. This suggests that the interruption of
LMX1B by translocation results in a loss of function
rather than a polypeptide with novel function or one
that interacts with the product of the normal allele in a
dominant-negative manner.
Of the six novel missense mutations, one mutates a
cysteine residue preserved in all LIM domains identified
to date, possibly disrupting the secondary structure of
the domain, and three have been shown to reduce or
abolish DNA binding (fig. 2). Homeodomain-DNA in-
teractions have been well studied since the original de-
scription of the family of homeotic genes in Drosophila.
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The studies have included footprinting, transactivation
assays, mobility-shift assays, and crystal structure de-
terminations (Gehring et al. 1994). The positions of
homeodomain missense mutations described in our co-
hort of NPS patients correlate well with residues known
to be important for secondary structure, binding spec-
ificity, and/or direct DNA-backbone interactions. For ex-
ample, the N-terminal arm of the homeodomain, con-
sisting of six amino acids, is thought to be flexible and
interacts with the DNA minor groove to determine se-
quence specificity for protein binding (Qian et al. 1989).
In vitro experiments mutating this region (either by de-
letion or by swapping) have resulted not only in loss of
DNA sequence specificity (Zeng et al. 1993), but also
in a 10-fold decrease in DNA binding affinity (Qian et
al. 1994). The third recognition helix is the most con-
served and directly interacts with the DNA major
groove. The N246K substitution, described by Dreyer
et al. (1998), affects an asparagine residue important in
mediating hydration and internal mobility of the hom-
eodomain-DNA complex (Qian et al. 1993). Similarly,
the arginine substitution in helix 2 (R226P) disrupts one
of two arginines that directly interact with the phosphate
backbone of the a-strand of the core DNA motif (Gehr-
ing et al. 1994). Finally, although the remaining residues
in helix 1 and helix 2 are not known to interact directly
with the DNA backbone, they do maintain the tertiary
structure important in the helix-turn-helix configuration,
which maintains direct DNA contact with the third he-
lix. According to secondary-structure predictions (data
not shown), the A213P substitution disrupts the a-helix
in this region by replacing it with a sterically restrained
amino acid, and this would be predicted to affect the
overall tertiary structure of the complex. At least in vitro,
the nature of the mutation correlates with a graded effect
on DNA binding. However, since early premature ter-
mination of the protein and these missense mutations
give similar phenotypes, it may be that these subtle dif-
ferences are not apparent in vivo in the context of the
cellular transcriptional apparatus. At the same time,
these data suggest that the mutant LMX1B proteins,
although unable to bind target DNA, do not act in a
dominant-negative manner on the transcription ap-
paratus.
Wilkie (1994) distinguishes between two categories of
genes, in disorders inherited in a dominant fashion, in
which mutations cause haploinsufficiency. In the first
group are genes, expressed in certain cells at high levels,
in which the 50% reduction in gene product results in
the phenotype (e.g., COL1A1 [MIM 120150] in osteo-
genesis imperfecta type I [MIM 166200] and COL2A1
[MIM 120140] in Stickler syndrome [MIM 108300;
Byers 1997]). The second group comprises regulatory
genes whose products are required at a certain level at
precise developmental stages (e.g., PAX3 [MIM 193500]
in Waardenburg syndrome [MIM 193500; Tassabehji et
al. 1993] and GLI3 [MIM 165240] in cephalopolysyn-
dactyly [MIM 175700; Vortkamp et al. 1991]). LMX1B
would appear to fit into the second category.
Comparison of phenotype with genotype (tables 1 and
2) did not reveal any correlation between disease severity
and type or location of mutation. The vast majority of
patients reported the typical orthopedic characteristics
of the syndrome, and the prevalence of kidney disease
was also close to that reported in earlier studies (Car-
bonara and Alpert 1964). Both nephropathy and kidney
disease, although less common than dysplasia of the
nails, patellae, and elbows, were present in families and
sporadic cases with nonsense, missense, or frameshift
mutations. Furthermore, patients bearing the R200Q
and R226P mutations, which had a less severe effect on
DNA binding than other missense mutations (fig. 2),
exhibited the same degree of phenotypic variability as
those in whom complete loss of function was assumed
(tables 1 and 2).
A recent study suggested that open-angle glaucoma
(OAG) may be part of the NPS phenotype (Lichter et
al. 1997). Of the patients in this study, seven reported
OAG (members of families 7, 14, 21, and 26), and in
two families glaucoma was reported along with NPS in
family members not available for testing (families 23 and
44). In addition, OAG was reported in two other families
in whom mutations have yet to be identified. Vollrath
et al. (1998) reported four loss-of-function mutations
that segregated with NPS and OAG, one of which re-
curred in family 5 in our study. It is of importance that
glaucoma was not reported in this family. These data
support the hypothesis that OAG is another aspect of
the pleiotropic NPS phenotype, and not due to coinci-
dence or a closely linked gene. Furthermore, a role for
Lmx1b during ocular development derives from the ob-
servation that lmx1b/ mice exhibit structural ab-
normalities of the anterior chamber of the eye (R. L.
Johnson, personal communication).
The correlation of LMX1B loss-of-function mutations
and the nail, patellar, and elbow dysplasia seen in NPS
reflects a disruption of normal dorsoventral patterning
of both hard and soft tissues in the limb. Similarly, the
renal and ocular manifestations in NPS likely result from
perturbations of different molecular pathways governing
the processes of patterning and cell differentiation in
these tissues. However, the specific actions of LMX1B
and of downstream and upstream effectors in these tis-
sues have yet to be determined.
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